SarahACooleyMD
Oncology • Minneapolis, MNAssistant Professor, Medicine, University of Minnesota Medical School
Dr. Cooley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
University of Minnesota Physicians
420 Delaware St SE MMC 136
Minneapolis, MN 55455Phone+1 612-624-5411Fax+1 612-273-2920
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2003 - 2006
University of California (San Francisco)Residency, Internal Medicine, 2000 - 2003- University of Minnesota Medical SchoolClass of 2000
Certifications & Licensure
CA State Medical License 2002 - Present
MN State Medical License 2003 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Study of Immune Response Modifier in the Treatment of Hematologic Malignancies Start of enrollment: 2006 Jan 01
- Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant Start of enrollment: 2005 Jan 01
- Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers Start of enrollment: 2006 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 49 citationsSystemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.Melissa M. Berrien-Elliott, Michelle Becker-Hapak, Amanda F. Cashen, Miriam T. Jacobs, Pamela Wong
Blood. 2021-11-19 - 8 citationsInfusion reactions in natural killer cell immunotherapy: a retrospective reviewTewodros Mamo, Shelly M. Williams, Stephanie Kinney, Katelyn M. Tessier, Todd E. DeFor
Cytotherapy. 2021-07-01 - 9 citationsFollowing Transplantation for Acute Myelogenous Leukemia, Donor KIR Cen B02 Better Protects against Relapse than KIR Cen B01.Lisbeth A. Guethlein, Niassan Beyzaie, Neda Nemat-Gorgani, Tao Wang, Vidhyalakshmi Ramesh
Journal of Immunology. 2021-06-11
Abstracts/Posters
- Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)Sarah Cooley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+ Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Fate Therapeutics Announces Five Presentations at the American Society of Gene & Cell Therapy 22nd Annual MeetingApril 24th, 2019
Fate Therapeutics Inc (NASDAQ:FATE) Institutional Investor PositioningMarch 10th, 2019
Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. As Senior Vice President, Clinical TranslationFebruary 20th, 2019
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
